Skip to content

Milestones

  • Company formation

  • May 2017

  • Convertible note financing

  • August 2019

  • Australian regulatory approval for Phase 1 study in patients with retinal detachment

  • October 2019

  • ONL1204 patent issued in US

  • March 2020

  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 2 (50 µg)

  • December 2020

  • Australian regulatory approval for Phase 1b study in patients with GA secondary to AMD

  • May 2021

  • First patient screened in GA Phase 1b clinical trial

  • October 2021

  • Series B financing – Tranche 2 closes

  • May 2022

  • GA Phase 1b – Open Label/Dose Escalation portion completed

  • November 2022

  • IND filed for ONL1204 Ophthalmic Solution

  • January 2023
  • February 2011

  • Series A financing

  • September 2018

  • Convertible note financing

  • October 2019

  • First patient dosed, first in human clinical trial in retinal detachment

  • December 2019

  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 1 (25 µg)

  • November 2020

  • Series B financing – Tranche 1 closes

  • January 2021

  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 3 (100 µg)

  • July 2021

  • First patient dosed in GA Phase 1b clinical trial (dose escalation phase)

  • January 2022

  • First patient dosed in OAG Phase 1b clinical trial

  • November 2022

  • RRD Phase 1 study completed

  • December 2022

  • IND open for ONL1204 Ophthalmic Solution (Phase 2 Retinal Detachment study)